Zacks Investment Research on MSN
IBRX stock jumps on progress in NK cell therapy production
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing engineering programs for its autologous memory cytokine-enhanced natural killer ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Eveo Cell Therapy Platform enables automated, multi-parallel intensified production of autologous cell therapies Compact design can increase output up to fourfold in existing cleanroom space 90 ...
At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
What is the current status of cell therapies today? It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the ...
InvestorsHub on MSN
HCW Biologics highlights positive findings for CAR-T therapy manufacturing
HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out ...
LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results